Table 2.
Antigen | Antibody levels induced by natural infection (EU/mL)* | Model | Duration ensuring antibody levels above those induced by natural infection in 95% participants (years) | |||
---|---|---|---|---|---|---|
Current study | Previous modelling study** | |||||
15–25 years old*** | 26–45 years old*** | 46–55 years old*** | 15–25 years old*** | |||
HPV–16 | 29.8 | Modified power-law | Lifelong | Lifelong | Lifelong | Lifelong |
Piecewise | 40.08 | 16.9 | 12.1 | 26.7 | ||
HPV–18 | 22.6 | Modified power-law | Lifelong | Lifelong | 4.3 years | Lifelong |
Piecewise | 19.2 | 9.0 | 5.1 | 19.9 |
Women aged 15–25 years in a previous study (NCT00689741 and NCT00120848).41
Age ranges indicate the ages of women at the time of the first vaccination dose.